The Sequencing Conundrum in Metastatic Castrate-resistant Prostate Cancer (mCRPC): the Rosemere Cancer Centre Experience to Unlocking the Optimal Sequence

被引：0
|
作者：
Pan, S. [1 ]
Kumar, V. [1 ]
Charnley, N. [1 ]
Parikh, O. [1 ]
Birtle, A. [1 ]
机构：
[1] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England
来源：
CLINICAL ONCOLOGY | 2016年 / 28卷 / 05期
关键词：
D O I：
10.1016/j.clon.2015.12.016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E14 / E14
页数：1
相关论文
共 50 条
  • [21] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [22] Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Mar, Nataliya
    Dwabe, Sami
    Baranda, Marlon N.
    Zarrabi, Kevin K.
    Eturi, Aditya
    Gulati, Shuchi
    Parikh, Mamta
    Seyedin, Steven N.
    Kalebasty, Arash Rezazadeh
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 217 - 223
  • [23] Use of low-dose, weekly carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
    O'Leary-Kelly, Meghan
    Gao, Dexiang
    Weisdack, Sarah
    Lam, Elaine Tat
    Bernard, Brandon David
    Flaig, Thomas W.
    Kessler, Elizabeth Riley
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [24] Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer (mCRPC).
    Marar, Mallika
    Long Qi
    Mamtani, Ronac
    Narayan, Vivek
    Vapiwala, Neha
    Parikh, Ravi Bharat
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [25] Seven Years of Clinical Experience Outcome Review on Radium 223 Therapy In Bone Metastatic Castrate-resistant Prostate Cancer (mCRPC)
    Cantinho-Lopes, M.
    Pena, H.
    Filipe, P.
    Mansinho, A.
    Fernandes, I.
    Costa, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S400 - S400
  • [26] Potential role of rituximab in metastatic castrate-resistant prostate cancer
    Bindal, Poorva
    Jalil, Sharif A. A.
    Holle, Lisa M.
    Clement, Jessica M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) : 1509 - 1511
  • [27] Retreatment of Men With Metastatic Castrate-Resistant Prostate Cancer With Abiraterone
    Leibowitz-Amit, Raya
    Alimohamed, Nimira
    Vera-Badillo, Francisco E.
    Seah, Jo-An
    Templeton, Arnoud J.
    Knox, Jennifer J.
    Tannock, Ian F.
    Sridhar, Srikala S.
    Joshua, Anthony M.
    PROSTATE, 2014, 74 (14): : 1462 - 1464
  • [28] Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer
    Nemtsova, E. R.
    Pankratov, A. A.
    Morozova, N. B.
    Tischenko, V. K.
    Petriev, V. M.
    Krylov, V. V.
    Shegay, P. V.
    Ivanov, S. A.
    Kaprin, A. D.
    BIOLOGY BULLETIN, 2022, 49 (12) : 2285 - 2297
  • [29] Radium-223 for Metastatic Castrate-Resistant Prostate Cancer
    Sindhu, Kunal K.
    Nehlsen, Anthony D.
    Stock, Richard G.
    PRACTICAL RADIATION ONCOLOGY, 2022, 12 (04) : 312 - 316
  • [30] Changing Treatment Landscape in the Initial Management of Metastatic Castrate-Resistant Prostate Cancer (mCRPC): An Australian Multi-Centre Retrospective Study
    Kwan, E.
    Semira, C.
    Muttiah, C.
    Beck, S.
    Anton, A.
    Tran, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 48 - 49
12345